Premium
A Review of Protease Inhibitor‐Induced Hyperglycemia
Author(s) -
Kaufman Michele B.,
Simionatto Creuza
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.1.114.30514
Subject(s) - protease inhibitor (pharmacology) , diabetes mellitus , medicine , protease , adverse effect , family history , human immunodeficiency virus (hiv) , antiretroviral therapy , plasma glucose , endocrinology , virology , viral load , biology , enzyme , biochemistry
Hyperglycemia is an adverse effect that occurs with all protease inhibitors, although few cases have been reported in the literature. Most patients with human immunodeficiency virus infection receiving antiretroviral therapy are also taking at least one protease inhibitor. Patients with a family history of diabetes mellitus may be at a greater risk of developing this adverse effect. It is therefore prudent to monitor all patients starting protease inhibitor therapy for the onset of diabetes or hyperglycemia, particularly those with a family history of diabetes. Baseline fasting plasma glucose or serum glucose level should be measured with follow‐up measurements every 3 months for approximately 6–12 months.